Document Detail

A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia.
MedLine Citation:
PMID:  16167938     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Plasma volume expansion may benefit both mother and child in the temporising management of severe and early onset hypertensive disorders of pregnancy.
DESIGN: Randomised clinical trial. Setting Two university hospitals in Amsterdam, The Netherlands.
POPULATION: Two hundred and sixteen patients with a gestational age between 24 and 34 completed weeks with severe pre-eclampsia, haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome or severe fetal growth restriction (FGR) with pregnancy-induced hypertension, admitted between 1 April 2000 and 31 May 2003.
METHODS: One hundred and eleven patients were randomly allocated to the treatment group, (plasma volume expansion and a diastolic BP target of 85-95 mmHg) and 105 to the control group (intravenous fluid restriction and BP target of 95-105 mmHg).
MAIN OUTCOME MEASURES: Neonatal neurological development at term age (Prechtl score), perinatal death, neonatal morbidity and maternal morbidity.
RESULTS: Baseline characteristics were comparable between groups. The median gestational age was 30 weeks. In the treatment group, patients received higher amounts of intravenous fluids (median 813 mL/day vs 14 mL/day; P < 0.001) with a concomitant decreased haemoglobin count (median -0.6 vs-0.2 mmol/L; P < 0.001). Neither neurological scores nor composite neonatal morbidity differed. A trend towards less prolongation of pregnancy (median 7.4 vs 11.5 days; P= 0.054) and more infants requiring oxygen treatment >21% (66 vs 46; P= 0.09) in the treatment group was observed. There was no difference in major maternal morbidity (total 11%), but there were more caesarean sections in the treatment group (98%vs 90%; P < 0.05).
CONCLUSION: The addition of plasma volume expansion in temporising treatment does not improve maternal or fetal outcome in women with early preterm hypertensive complications of pregnancy.
Wessel Ganzevoort; Annelies Rep; Gouke J Bonsel; Willem P F Fetter; Loekie van Sonderen; Johanna I P De Vries; Hans Wolf;
Related Documents :
3679448 - The possible role of digitalislike factors in pregnancy-induced hypertension.
17519778 - Pregnancy after organ transplantation: a report from the uk transplant pregnancy registry.
2794958 - Hypertensive disorders in pregnancy: analysis of 110 cases.
675128 - Plasmatic level of angiotensin i in normal subjects of various ages, in cushing's syndr...
7123828 - Effect of progesterone treatment on the calving-to-conception interval of friesian dair...
8839628 - Plasma bovine placental lactogen concentration throughout pregnancy in the cow; relatio...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  112     ISSN:  1470-0328     ISO Abbreviation:  BJOG     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-09-19     Completed Date:  2005-12-05     Revised Date:  2014-07-29    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  1358-68     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Blood Pressure / physiology
Body Weight
Fluid Therapy / methods
Hydroxyethyl Starch Derivatives / therapeutic use
Plasma Substitutes / therapeutic use*
Pre-Eclampsia / therapy*
Pregnancy Outcome
Reg. No./Substance:
0/Antihypertensive Agents; 0/Hydroxyethyl Starch Derivatives; 0/Plasma Substitutes
Comment In:
BJOG. 2005 Oct;112(10):1337-8   [PMID:  16167934 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A population-based study of the prenatal diagnosis of congenital malformation over 16 years.
Next Document:  The future of prenatal diagnosis: rapid testing or full karyotype? An audit of chromosome abnormalit...